SCYNEXIS (NASDAQ:SCYX) Releases Quarterly Earnings Results, Beats Expectations By $0.13 EPS

SCYNEXIS (NASDAQ:SCYX) released its quarterly earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.13, Zacks reports. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%.

SCYNEXIS Price Performance

SCYX stock opened at $0.91 on Thursday. SCYNEXIS has a 12 month low of $0.88 and a 12 month high of $3.07. The company’s 50 day simple moving average is $1.11 and its 200-day simple moving average is $1.26. The firm has a market capitalization of $34.61 million, a PE ratio of -1.23 and a beta of 1.67.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.